MiNK-215 / Agenus - LARVOL DELTA

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors (GlobeNewswire) - "This collaboration will leverage Autonomous’ precision encrypted RNA (encRNA) technology and MiNK’s innovative iNKT cell therapies, MiNK-215 and agenT-797....The goal is to develop novel therapies that effectively target metastatic cancer cells in patients while avoiding healthy cells—a challenge that existing cancer medicines have not been able to overcome. Based on the results, the companies plan to launch a Phase 1 clinical trial in patients with treatment-refractory metastatic solid tumors, including microsatellite stable (MSS) colorectal cancers."

Licensing / partnership • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

MiNK Reports Second Quarter 2024 Results and Business Update (GlobeNewswire) - "A Phase 2 Investigator-Sponsored Study of agenT-797 is progressing rapidly at Memorial Sloan Kettering Cancer Center (NCT06251973). The study’s swift advancement and early signals of activity highlight the promising potential of agenT-797 in treating challenging cancers, with initial data at an upcoming conference....MiNK-215 is an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, that has demonstrated robust preclinical activity in solid tumor cancers, including MSS colorectal cancer liver metastases, and non-small-cell-lung cancer. Plans are in place to fast-track the IND filing to early 2025."

IND • P2 data • Colorectal Cancer • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer (GlobeNewswire) - "This capital injection is earmarked for accelerating the clinical trials of MiNK-215, our leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein (FAP) in solid tumors, which is planned to enter the clinic in early 2025."

Financing • New trial • Oncology • Solid Tumor

MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy, effectively treats human organoid models of treatment-refractory MSS colorectal cancer (CRC) liver metastases (AACR 2024) - "Here we describe MiNK-215, an IL-15 armored FAP-targeting CAR iNKT cell therapy, derived from the AgenT-797 allogeneic iNKT platform, as a potential novel therapeutic approach for patients with CRC liver metastases.To better model ICB refractory human MSS CRC liver metastases, we developed an ex vivo human organoid model that recapitulates the histological and immunological features of human disease...Models were treated with Fc-enhanced anti-CTLA-4 (botensilimab) and anti-PD-1 (balstilimab) antibodies, or MiNK-215 to assess tumor killing and immune activation.Botensilimab and balstilimab enhanced T cell activation and cytotoxicity of CRC tumor cells in the absence of "normal" liver cells and in lung organoids...Tumor killing in CRC liver organoid models by MiNK-215 was associated with depletion of immune suppressive FAP-expressing stellate cells and increased CD8+ T cell infiltration.Our findings demonstrate that in treatment-refractory CRC-liver metastatic..."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD8 • CTAG1B • FAP • IL15

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR (GlobeNewswire) - "MiNK Therapeutics...announced the presentation of data from MiNK-215, an investigational IL-15 armored fibroblast activation protein (FAP) targeting CAR-iNKT cell therapy, at the American Association for Cancer Research (AACR) Meeting....MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models. MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation."

Preclinical • Colorectal Cancer

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024 (GlobeNewswire) - "MiNK Therapeutics, Inc...announced the presentation of preclinical data from MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, at the upcoming AACR Meeting, to be held April 5 – 10, 2024 in San Diego, CA....In human organoid models of CRC with liver metastases, MiNK-215 potently enhanced tumor killing by T cells and was associated with depletion of immune suppressive FAP-expressing stellate cells and increased CD8+ T cell infiltration."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

MiNK Therapeutics Reports Second Quarter 2023 Results (GlobeNewswire) - "MiNK-215: IND enabling studies are underway; IND filing on track for 2024."

IND • Oncology • Solid Tumor

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT (GlobeNewswire) - "MiNK Therapeutics...presented preclinical data demonstrating the potential of its novel FAP-CAR-iNKT candidate, MiNK-215, at the American Society of Gene and Cell Therapy (ASGCT) annual meeting....FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models. IND enabling studies underway; IND filing on track for 2024."

IND • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

Development of an Allogeneic FAP-CAR iNKT Cell Therapy to Modulate the Immunosuppressive Stroma and Improves Anti-Tumor Immunity Against Non-Small Cell Lung Carcinoma (ASGCT 2023) - "Taken together, we demonstrate that targeting FAP-expressing CAFs with MiNK-215 cell therapy has the capability to promote a productive therapeutic response and expand survival in solid tumor models. Furthermore, it represents an attractive off-the-shelf allogenic cell therapy in a broad range of solid tumor cancers."

IO biomarker • Stroma • Hematological Disorders • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CAFs • CD8 • IFNG • IL15

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) - "Anticipated Upcoming Milestones: Present updated clinical data readout from phase 1 study of agenT-797 full solid tumor cohort at AACR Annual Meeting, April 2023...Launch expansion combination studies with agenT-797 in NSCLC and Gastric in 2023; FAP-CAR-iNKT IND filing in 2024."

IND • New trial • P1 data • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline (GlobeNewswire) - "MiNK Therapeutics...announced the presentation of new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting....MiNK’s FAP-CAR-iNKT therapeutic candidate, MiNK-215, demonstrates robust efficacy in non small cell lung cancer (NSCLC) preclinical models, promoting curative responses, eliminating tumor burden in the lungs, and enhancing tumor specific CD8+ T cell infiltration through tumor stroma. FAP-CAR-iNKT demonstrates a drastic increase of CD8+ T cells infiltrating the tumor and significantly increased tumor killing compared to T cells in murine models."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results (GlobeNewswire) - "Five abstracts accepted for presentation at Society of Cancer Immunotherapy 37th Annual Meeting, November 8th to 12th: (i) Clinical data from agenT-797 (allo-iNKTs) alone or in combination with anti-PD-1 in advanced solid tumor cancers, severe viral ARDS, and relapsed/refractory multiple myeloma; (ii) Data on our new therapeutic candidates, MiNK-215, a novel FAP-CAR-iNKT, and MiNK-413, a differentiated allogeneic armored-BCMA-CAR-iNKT; (iii) First reports of novel mechanisms of agenT-797, improving effector functions within the tumor microenvironment."

Clinical data • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor